Loyal, based in San Francisco, California, is dedicated to developing drugs that extend and enhance the health and lifespan of dogs. With a core mission to help dogs live longer and healthier lives, Loyal focuses on preventive care by addressing the underlying causes of age-associated diseases. Their products, such as LOY-002 for senior dogs, aim to delay the onset of these diseases and reduce their impact, targeting dogs aged 10 and older.
Notable affiliated individuals include experts in veterinary medicine and biotechnology, though specific names are not provided. Loyal has achieved significant milestones in drug development and clinical trials, positioning itself as a leader in canine health innovation. The company's impact is evident in its commitment to improving the quality of life for aging dogs, offering hope to pet owners seeking to extend the time they have with their beloved companions.
